<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-548
Date of Submission: 2025-02-19

This report was submitted by a Other Healthcare Professional from Johnson, Crawford and Ward Medical Center concerning patient ANON-PX-8649. The subject is a 27-year-old other with a significant medical history including anxiety, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Oral route at a dosage of 491mg, initiated on 2024-12-29 for Hypercholesterolemia with the course ongoing; Omeprazole (Proton-pump inhibitor) administered via the Subcutaneous route at a dosage of 303mg, initiated on 2024-12-29 for Gastroesophageal reflux disease with the course ongoing.

On approximately 2025-01-15, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Somnolence. The Dizziness was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed project and advised task. The current patient status regarding this symptom is 'Fatal'. The Somnolence was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 2 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Value sign general husband cold.</data>
report_id: ADR-2025-548
report_date: '2025-02-19'
patient_details:
  patient_id: ANON-PX-8649
  gender: Other
  relevant_history:
  - anxiety
  - asthma
  age_at_reaction: 27
suspected_drugs:
- drug_name: Atorvastatin
  dosage: 491mg
  route_of_administration: Oral
  start_date: '2024-12-29'
  indication_for_use: Hypercholesterolemia
  drug_class: Statin
- drug_name: Omeprazole
  dosage: 303mg
  route_of_administration: Subcutaneous
  start_date: '2024-12-29'
  indication_for_use: Gastroesophageal reflux disease
  drug_class: Proton-pump inhibitor
adverse_reactions:
- symptom_name: Dizziness
  onset_date: '2025-01-15'
  severity: Moderate
  outcome: Fatal
  intervention_required: true
  intervention_details: Prescribed project and advised task.
- symptom_name: Somnolence
  onset_date: '2025-01-15'
  severity: Moderate
  outcome: Recovering
  intervention_required: false
causality_assessment:
  assessment_conclusion: Possible
  dechallenge_rechallenge: Positive dechallenge
  naranjo_score: 2
reporting_facility: Johnson, Crawford and Ward Medical Center
reporter_type: Other Healthcare Professional
notes: Value sign general husband cold.
